Author Archive

Survey Results: The collapse of the euro and pharmaceutical reference pricing – a challenge or opportunity?

Posted by:

Last week we posed the question of what consequences a possible collapse of the euro would have on pharmaceutical pricing policies. We asked a number of leading experts and pharmaceutical insiders how the replacement of the euro with national currencies would affect pharmaceutical pricing in Europe.

Today we publish the results of this survey. As you can see from the below graph a clear majority of survey respondents thought that the replacement of the euro with national currencies would increase the ...

Continue Reading →
0

Commercialization Memoranda

Posted by:

Will the Obama administration’s recently issued memoranda have a noticeable effect on technology transfer, IP commercialization and small business growth?


With his Jobs Bill still pending in Congress, on October 28th President Obama announced a series of measures and instructions to the federal government and its agencies to try and help stimulate the economy. The measures were outlined in two presidential memoranda: “Accelerating Technology Transfer and Commercialization of Federal Research in Support of High-Growth Businesses” (Memoranda 1) and “Making ...

Continue Reading →
0

Cap and Innovate?

Posted by:

California’s introduction last month of a cap-and-trade system to limit and reduce the emissions of carbon dioxide and other pollutants may mark a new phase in the American climate change debate. The decision by the California Air Resources Board to put a price on heat-trapping pollution and allow polluting industries to trade carbon credits adds to California’s already substantial number of climate changes related laws and regulations.

The key question is, of course, if it will lead to an increase ...

Continue Reading →
0
Page 5 of 5 12345